Elsevier

Vaccine

Volume 35, Issue 35, Part A, 16 August 2017, Pages 4486-4489
Vaccine

A novel combination adjuvant platform for human and animal vaccines

https://doi.org/10.1016/j.vaccine.2017.05.067Get rights and content

Abstract

Adjuvants are crucial components of many vaccines. They are used to improve the immunogenicity of vaccines with the aim of conferring long-term protection, to enhance the efficacy of vaccines in newborns, elderly or immunocompromised persons, and to reduce the amount of antigen or the number of doses required to elicit effective immunity. Novel combination adjuvants have been tested in both candidate animals and humans vaccines and have generated encouraging results. Recently, we developed a combination adjuvant platform (TriAdj) comprising of three components, namely a TLR agonist, either polyI:C or CpG oligodeoxynucleotides (ODN), host defense peptide and polyphosphazene. This adjuvant platform is stable and highly effective in a wide range of animal and human vaccines tested in mice, cotton rats, pigs, sheep, and koalas. TriAdj with various vaccines antigens induced effective long-term humoral and cellular immunity. Moreover, the adjuvant platform is suitable for maternal immunization and highly effective in neonates even in the presence of maternal antibodies. This novel vaccine platform, offers excellent opportunity for use in present and future generations of vaccines against multiple infectious agents and targets challenging populations.

Introduction

Vaccines provide significant public health benefits by reducing the burden of infectious diseases. Live vaccines generate effective immune responses, but have been associated with a number of safety concerns, including improper attenuation, the occasional presence of adventitious agents and reverting back to virulence. Non-replicating vaccines i.e. whole, inactivated viruses and specifically recombinant or highly purified subunit antigens are often weakly immunogenic and need to be formulated with adjuvants to enhance their immunogenicity and induce robust antibody and effector T cell responses to prevent infections. Adjuvants are an essential part of vaccines, usually used to stimulate faster, stronger, and long-lasting immune responses to vaccines and thus can be used for enhancing immune responses to vaccine antigens, providing faster onset of immunity, improving immune responses to immunization in infant or elderly populations, whose immune system are immature or waning, reducing the immunization schedule and dose sparing, which implies reducing the quantity of antigen required in the vaccine preparation [1]. Adjuvants are often required in subunit vaccines due to the poor immunogenicity of such antigens.

There is no single adjuvant that can include all the vaccine requirements. Using a single adjuvant has a number of limitations, including induction of weak, improper, and short-lived immune responses. For example, alum and MF59 [2] are the universally approved adjuvants for human vaccines. Both normally induce Th2-biased immune responses but only weak cytotoxic immune responses, as required for protection against intracellular pathogens such as viruses, invasive bacteria and protozoa. In contrast, when multiple adjuvants are used in combination they can act synergistically by stimulating and activating various types of immune cells such as dendritic cells, macrophages, lymphocytes etc. A combination adjuvant platform is promising and beneficial for suboptimal vaccines and particularly advantageous for vaccines against specific and more susceptible populations, such as neonates and the older adults. In some respects the neonatal immune system is similar to that of the elderly since they both are having diminished anti-microbial activity by immune cells, reduced antigen-uptake and -presentation by antigen presenting cells and compromised adaptive immune responses [3]. Combination adjuvants may therefore provide an approach to boost immune responses in both neonates and the elderly. Often these combinations are comprised of a delivery system and an immunostimulatory adjuvant, especially combinations with toll-like receptor (TLR) agonists and monophosphoryl lipid A (MPL). Combination adjuvants such as Montanides, ISCOMs, Liposomes etc. formulated with or without other adjuvants have been tested in humans and animals and have generated promising result [4], [5], [6], [7], [8], [9], [10]. Recently, we developed a novel combination adjuvant platform (TriAdj) that is highly effective with a wide range of animal and human antigens.

Section snippets

Combination adjuvant platform for animal vaccines

Veterinary vaccines have been used for several years and play an important role in promoting animal health, welfare, food production, and public health. They are a cost-effective method to protect animals from disease, improve food production, and reduce the need for antibiotics in food and companion animals. Furthermore, vaccines are essential in preventing transmission of zoonotic disease to humans. Interestingly, there are unique challenges with respect to animal vaccines including the need

Combination adjuvant platform for human vaccines

Several combination adjuvants consisting of a variety of immunomodulators such as Immune Stimulating Complexes (ISCOMs), montanides, nanoemulsions, and adjuvant systems have been developed in recent years and are currently being tested with human vaccines in preclinical and clinical trials. The novel adjuvant platform, TriAdj, was co-formulated with various human vaccine antigens and tested in animal models including mice, cotton rats, pigs and sheep. This adjuvant platform is highly effective

Mechanisms of action of the combination adjuvant

Various mechanisms of action were identified for this novel combination adjuvant. For example, TriAdj used as a mucosal (intranasal) adjuvant increased antigen uptake by dendritic cells, improved dendritic cell maturation, and more efficiently transported the antigen to local draining lymph nodes to present it to T cells [17]. TriAdj-formulated antigen promoted the production of chemokines, cytokines and inflammatory cytokines, followed by recruitment and activation of several immune cell

Future perspectives

As our understanding of the immune system develops, and in particular its linkages between innate and adaptive immunity, combination adjuvants will continue to emerge that include multiple danger signals resulting in sophisticated and tailor-made responses that are based on stimulation of multiple receptors and signalling pathways in a multitude of immune cells. In particular, with the advent of precision medicine and the role of the microbiome in shaping the immune response to vaccination,

Acknowledgments

Research in the authors’ laboratories is supported from a variety of funding agencies including the Krembil Foundation – Canada, the Bill and Melinda Gates Foundation – United States, the Canadian Institutes of Health Research (CIHR), the National Science and Engineering Research Council (NSERC), the Saskatchewan Health Research Foundation (SHRF), the Alberta Livestock and Meat Agency (ALMA), the Saskatchewan Agriculture Development Fund (ADF), and the Pan-Provincial Vaccine Enterprise. The

References (42)

  • M. Snider et al.

    The bovine viral diarrhea virus E2 protein formulated with a novel adjuvant induces strong, balanced immune responses and provides protection from viral challenge in cattle

    Vaccine

    (2014)
  • S.A. Khan et al.

    Vaccination of koalas (Phascolarctos cinereus) with a recombinant chlamydial major outer membrane protein adjuvanted with poly I:C, a host defense peptide and polyphosphazine, elicits strong and long lasting cellular and humoral immune responses

    Vaccine

    (2014)
  • M. Polewicz et al.

    Influence of maternal antibodies on active pertussis toxoid immunization of neonatal mice and piglets

    Vaccine

    (2011)
  • A. Gracia et al.

    Antibody responses in adult and neonatal BALB/c mice to immunization with novel Bordetella pertussis vaccine formulations

    Vaccine

    (2011)
  • M. Polewicz et al.

    Novel vaccine formulations against pertussis offer earlier onset of immunity and provide protection in the presence of maternal antibodies

    Vaccine

    (2013)
  • D.H. Shim et al.

    Efficacy of poly[di(sodium carboxylatophenoxy)phosphazene] (PCPP) as mucosal adjuvant to induce protective immunity against respiratory pathogens

    Vaccine

    (2010)
  • R. Garg et al.

    Maternal immunization with respiratory syncytial virus fusion protein formulated with a novel combination adjuvant provides protection from RSV in newborn lambs

    Vaccine

    (2016)
  • S. Garlapati et al.

    Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles

    Vaccine

    (2012)
  • I. Sarkar et al.

    Formulation of the respiratory syncytial virus fusion protein with a polymer-based combination adjuvant promotes transient and local innate immune responses and leads to improved adaptive immunity

    Vaccine

    (2016)
  • R. Garg et al.

    A single intranasal immunization with a subunit vaccine formulation induces higher mucosal IgA production than live respiratory syncytial virus

    Virology

    (2016)
  • R.T. Kenney et al.

    Survey of human-use adjuvants

    Expert Rev Vaccines

    (2003)
  • Cited by (0)

    View full text